FDA Expands Approval of LUMRYZ for Pediatric Narcolepsy
The FDA has approved Avadel Pharmaceuticals’ LUMRYZ for pediatric patients aged 7 and older with narcolepsy, offering a once-nightly treatment for cataplexy and excessive daytime sleepiness.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
